UNSPSC 51351611: Estropipate

This classification denotes a steroidal estrogen with the molecular formula C18H22O5S.C4H10N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SVI38UY019, chemically known as 3-(sulfooxy)estra-1,3,5(10)-trien-17-one, w/pip* but generally known as estropipate, which bears US NIH Compound Identifier 23703. European Medicines Agency schedules Estropipate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13724MIG. As of Q4 2014, ESTROPIPATE remains the US FDA Preferred Term for this commodity.

Estropipate bears US NLM identifiers UMLS ID C0071108 and NCI Concept Code C47521. SMILES: S(=O)(=O)(Oc1cc2c(C3C(C4C(CC3)(C(=O)CC4)C)CC2)cc1)O.N1CCNCC1.

UNSPSC 51351611 Estropipate is a Commodity code encompassing pharmaceutical products that state and local governments procure through cooperative purchasing vehicles and direct contracts with manufacturers. The code captures the supply of generic estropipate — an estrogen replacement therapeutic — as part of broader multistate pharmaceutical procurement programs serving state agencies, local health departments, correctional facilities, and other government healthcare systems. Recent solicitations under this code involve manufacturers competing to supply pharmaceutical products meeting FDA standards, current Good Manufacturing Practices (cGMP), and Drug Supply Chain Security Act (DSCSA) compliance, typically bundled into multi-source generic and over-the-counter product frameworks rather than as standalone line items. Issuers are primarily state cooperative purchasing organizations and state departments of health or administration that aggregate demand across multiple participating jurisdictions and member facilities.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted the primary recent opportunity on January 20, 2026 — a Request for Proposal (RFP) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products with a March 26, 2026 response deadline. The MMCAP solicitation encompasses participating states including Minnesota and Oregon, requiring manufacturers to supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) with pricing available by May 15, 2026 and contracts effective July 1, 2026. Evaluation weighs price competitiveness at 75 percent, with smaller weights on fixed pricing, administrative compliance, EDI capability, and administrative fee structure. Vendors must maintain significant insurance coverage including $5 million commercial general liability per occurrence and demonstrate contractual relationships with at least two of the three authorized wholesalers with functioning chargeback systems in place.